MOESM4 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Schernthaner, Guntram; Lehmann, Roger; Prázný, Martin; Czupryniak, Leszek; Ducena, Kristine; Fasching, Peter; Janež, Andrej; Karasik, Avraham; Kempler, Peter; Martinka, Emil; Shestakova, Marina; Duvnjak, Lea; Tankova, Tsvetalina

doi:10.6084/m9.figshare.c.3911593_D4.v1

12933_2017_622_MOESM4_ESM.docx (14.53 kB)

MOESM4 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

journal contribution

posted on 2017-10-23, 05:00 authored by Guntram Schernthaner, Roger Lehmann, Martin Prázný, Leszek Czupryniak, Kristine Ducena, Peter Fasching, Andrej Janež, Avraham Karasik, Peter Kempler, Emil Martinka, Marina Shestakova, Lea Duvnjak, Tsvetalina Tankova

Additional file 4: Table S1. Selected outcomes from SGLT2 inhibitor CVOTs.

Funding

Boehringer Ingelheim

History

Usage metrics

Keywords

Type 2 diabetes Anti-glycaemic drugs Cardiovascular disease Renal disease

Licence

CC BY + CC0

Exports

RefWorks

BibTeX

Ref. manager

Endnote

DataCite

NLM

DC

MOESM4 of Translating recent results from the Cardiovascular Outcomes Trials into clinical practice: recommendations from the Central and Eastern European Diabetes Expert Group (CEEDEG)

Funding

Boehringer Ingelheim

History

Usage metrics

Categories

Keywords

Licence

Exports